Novel Tacrine-Benzofuran Hybrids As Potent Multitarget-Directed Ligands for the Treatment of Alzheimer'S Disease: Design, Synthesis, Biological Evaluation, and X-Ray Crystallography
Xiaoming Zha,Doriano Lamba,Lili Zhang,Yinghan Lou,Changxu Xu,Di Kang,Li Chen,Yungen Xu,Luyong Zhang,Angela De Simone,Sarah Samez,Alessandro Pesaresi,Jure Stojan,Manuela G. Lopez,Javier Egea,Vincenza Andrisano,Manuela Bartolini
DOI: https://doi.org/10.1021/acs.jmedchem.5b01119
IF: 8.039
2015-01-01
Journal of Medicinal Chemistry
Abstract:Twenty-six new tacrine-benzofuran hybrids were designed, synthesized, and evaluated in vitro on key molecular targets for Alzheimer's disease. Most hybrids exhibited good inhibitory activities on cholinesterases and β-amyloid self-aggregation. Selected compounds displayed significant inhibition of human β-secretase-1 (hBACE-1). Among the 26 hybrids, 2e showed the most interesting profile as a subnanomolar selective inhibitor of human acetylcholinesterase (hAChE) (IC50 = 0.86 nM) and a good inhibitor of both β-amyloid aggregation (hAChE- and self-induced, 61.3% and 58.4%, respectively) and hBACE-1 activity (IC50 = 1.35 μM). Kinetic studies showed that 2e acted as a slow, tight-binding, mixed-type inhibitor, while X-ray crystallographic studies highlighted the ability of 2e to induce large-scale structural changes in the active-site gorge of Torpedo californica AChE (TcAChE), with significant implications for structure-based drug design. In vivo studies confirmed that 2e significantly ameliorates performances of scopolamine-treated ICR mice. Finally, 2e administration did not exhibit significant hepatotoxicity.